Company Filing History:
Years Active: 2023-2025
Title: Innovator Frank Kuhnert: Pioneering Antibody-Drug Conjugate Therapies
Introduction
Frank Kuhnert is a notable inventor residing in Cortlandt Manor, NY, with a focus on groundbreaking advancements in cancer treatment. With a total of two patents to his name, Kuhnert's work significantly contributes to the evolving field of immunotherapy, particularly in the realm of targeted therapies.
Latest Patents
Kuhnert's latest innovations include two notable patents. The first patent involves "IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer." This disclosure presents methods for treating or inhibiting tumor growth by administering a therapeutically effective amount of both an IL-4/IL-13 pathway inhibitor and a programmed death 1 (PD-1) inhibitor. This approach aims to enhance the anti-tumor efficacy of PD-1 blockade, providing new hope for patients battling cancers.
The second patent details "Anti-PTCRA antibody-drug conjugates and uses thereof." This innovative work encompasses antibody-drug conjugates (ADCs) containing anti-PTCRA antibodies, with proposed methods for their use. These ADCs are particularly advantageous for treating T-cell acute lymphoblastic leukemia (T-ALL) and other diseases characterized by elevated PTCRA expression, marking a significant stride in targeted cancer therapies.
Career Highlights
Frank Kuhnert is affiliated with Regeneron Pharmaceuticals, Inc., a company renowned for its dedication to developing cutting-edge medicines. His role at Regeneron allows him to collaborate with talented professionals and contribute to the advancement of medical science through innovative drug development.
Collaborations
Throughout his career, Kuhnert has worked alongside knowledgeable colleagues such as Michael Van Meter and Thomas Nittoli. These collaborations foster a creative and productive environment, allowing for the exchange of ideas and expertise that drive innovation in cancer treatment strategies.
Conclusion
Frank Kuhnert's contributions to the field of cancer therapy demonstrate a commitment to enhancing patient outcomes through innovation. With his latest patents addressing critical aspects of tumor treatment and leveraging collaborative efforts at Regeneron Pharmaceuticals, Kuhnert remains a pivotal figure in the ongoing battle against cancer. His work exemplifies the power of invention in shaping the future of medicine.